Morgan Stanley’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-95,763
| Closed | -$17K | – | 8129 |
|
|
2022
Q3 | $17K | Sell |
95,763
-11,003
| -10% | -$1.95K | ﹤0.01% | 6878 |
|
|
2022
Q2 | $64K | Sell |
106,766
-34,102
| -24% | -$20.4K | ﹤0.01% | 6504 |
|
|
2022
Q1 | $186K | Sell |
140,868
-130,409
| -48% | -$172K | ﹤0.01% | 5966 |
|
|
2021
Q4 | $708K | Buy |
271,277
+122,115
| +82% | +$319K | ﹤0.01% | 5328 |
|
|
2021
Q3 | $464K | Buy |
149,162
+20,081
| +16% | +$62.5K | ﹤0.01% | 5547 |
|
|
2021
Q2 | $480K | Buy |
129,081
+30,620
| +31% | +$114K | ﹤0.01% | 5545 |
|
|
2021
Q1 | $340K | Sell |
98,461
-9,988
| -9% | -$34.5K | ﹤0.01% | 5365 |
|
|
2020
Q4 | $365K | Buy |
108,449
+6,799
| +7% | +$22.9K | ﹤0.01% | 5259 |
|
|
2020
Q3 | $356K | Sell |
101,650
-60,026
| -37% | -$210K | ﹤0.01% | 4808 |
|
|
2020
Q2 | $743K | Buy |
161,676
+76,053
| +89% | +$350K | ﹤0.01% | 4380 |
|
|
2020
Q1 | $284K | Sell |
85,623
-16,961
| -17% | -$56.3K | ﹤0.01% | 4709 |
|
|
2019
Q4 | $627K | Sell |
102,584
-48,870
| -32% | -$299K | ﹤0.01% | 4800 |
|
|
2019
Q3 | $631K | Buy |
151,454
+67,260
| +80% | +$280K | ﹤0.01% | 4574 |
|
|
2019
Q2 | $1.1M | Buy |
84,194
+81,963
| +3,674% | +$1.07M | ﹤0.01% | 4165 |
|
|
2019
Q1 | $21K | Buy |
+2,231
| New | +$21K | ﹤0.01% | 6000 |
|